Oncotarget Volume 10, Issue 5 features Figure 5, "PD-L1 function in RR cell lines," by Schulz, et al.
RR cells showed prolonged survival as well as delayed and diminished apoptosis after irradiation with vimentin expression but no E-cadherin expression, whereas RS cell lines died early and exhibited early apoptosis after irradiation and high vimentin expression.
Moreover, the research team observed a radiation dose dependent increase of total PD-L1 protein expression in RR cell lines up to 96h after irradiation compared to non-irradiated cells.
Co-immunoprecipitation experiments revealed decreased interaction of GSK-3beta with PD-L1 in non-IRR compared to irradiated RR cells leading to PD-L1 stabilization in RR cells.
Figure 5: PD-L1 function in RR cell lines. (A) WST-1 viability assay after siRNA knockdown of PD-L1 in RR HNSCC cell lines. All cell lines with PD-L1 knockdown showed a substantial decrease of proliferation compared to cells transfected with scrambled siRNA (NT) as control during the course of 96h. (B) The average doubling time of PD-L1 knockdown cells was 115,9h compared to NT control cells with 46,8h. NT= non-targeting, scrambled non-specific siRNA. Two-way ANOVA * = p < 0,05, ** = p < 0,01, *** = p < 0,001.
Prof Dr. Tobias Ettl from the Department of Oral and Maxillofacial Surgery, University Hospital Regensburg in Germany and the Center for Medical Biotechnology, said "With more than 600.000 new diagnosis each year head and neck squamous cell carcinoma is the 6th most common form of cancer worldwide with a strongly increasing incidence over the last 10 years.Recent studies show that PD-L1 expressing cancer cells have the ability to evade immune response. Multidisciplinary approach of irradiation combined with a blockade of the PD-1/PD-L1 axis showed remarkable clinical outcomes for various tumor entities and in patients with poor prognosis. However, a considerable part of HNSCC patients still shows little improvement or even hyperprogression."
"With more than 600,000 new diagnoses each year, head and neck squamous cell carcinoma is the 6th most common form of cancer worldwide with a strongly increasing incidence over the last 10 years. Recent studies show that PD-L1 expressing cancer cells have the ability to evade immune response. Multidisciplinary approach of irradiation combined with a blockade of the PD-1/PD-L1 axis showed remarkable clinical outcomes for various tumor entities and in patients with poor prognosis. However, a considerable part of HNSCC patients still shows little improvement or even hyperprogression."
- Prof Dr. Tobias Ettl, Department of Oral and Maxillofacial Surgery, University Hospital Regensburg
PD-L1 expression is common in many solid human cancers including colorectal cancer, gastric cancer, esophageal cancer, hepatocellular carcinoma, melanoma, glioblastoma, lung cancer, and oral squamous cell carcinoma .
Together with PD Dr. Richard Bauer and Daniela Schulz from the Center for Medical Biotechnolgy in Regensburg, they investigate the tumor cell intrinsic function of PD-L1 which they suggest to be dependent on the basic molecular setup of tumor cells. This setup determines raidoresistancy or radiosensitivity and principally the expression, localization, interaction and function of proteins such as PD-L1. Therefore,in this study the team examined PD-L1 expression and cell intrinsic function in radioresistant and radiosensitive HNSCC cell lines before and after irradiation.
The Bauer research team concluded, in their Oncotarget Research Paper, "Our data suggest a longer turnover time of PD-L1 in IRR RR cells due to GSK-3beta inactivation and subsequent PD-L1 stabilization."
Sign up for free Altmetric alerts about this article
DOI - https://doi.org/10.18632/oncotarget.26542
Full text - https://www.oncotarget.com/article/26542/text/
Correspondence to - Richard Josef Bauer - [email protected]
Keywords - PD-L1, immune checkpoint, head and neck cancer, irradiation, GSK-3beta
About Oncotarget
Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit https://www.impactjournals.com/ or connect with @ImpactJrnls
Media Contact
[email protected]
18009220957x105
